Meet GSK management
Getting ahead of infectious diseases
Interactive event for investors and analysts. This webinar is being recorded.
Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk factors’ in the Group’s Annual Report on Form 20-F for the full year (FY) 2022 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q1 2023 earnings release and Annual Report on Form 20-F for FY 2022.

All guidance, outlooks, ambitions and expectations should be read together with the Guidance, assumptions and cautionary statements in GSK’s Q1 2023 earnings release and the 2022 Annual Report.

Basis of preparation: GSK satisfied the formal criteria according to IFRS 5 for treating Consumer Healthcare as a ‘Discontinued operation’ effective from 30 June 2022. On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.
Agenda

Getting ahead of infectious disease
- Emma Walmsley

World leader in infectious diseases R&D
- Dr Tony Wood

Delivering profitable growth to 2026 and beyond
- Luke Miels

Breakout sessions

Breakout 1: Seasonal respiratory viruses
- Dr Phil Dormitzer and Christi Kelsey

Breakout 2: Bacterial and fungal infections
- Dr Kumaran Vadivelu and Rob Bowers

Breakout 3: Chronic viral infections
- Chris Corsico, Lizzie Champion and James Greenhalgh

Breakout 4: Delivering health impact at scale
- Deborah Waterhouse and Dr Thomas Breuer

Q&A
Getting ahead of infectious disease

Emma Walmsley, Chief Executive Officer
A focused global biopharma company with strong momentum and big ambitions

- Unique strategy focused on prevention and treatment of disease
- World leader in infectious diseases with an attractive broader pipeline based on the science of the immune system and advanced technology
- Competitive medium-term sales and profit outlook supported by landmark 2022 and continued momentum
- Confident in ability to sustain profitable growth through decade and beyond to deliver human health impact at scale

Meet GSK management series 2023

Three virtual events highlighting GSK’s growth prospects and expertise in preventing and treating disease

- Infectious diseases
- HIV
- Immunology/Respiratory

Potential first- or best-in-class vaccines and medicines that offer potential future sales and profitable growth in targeted and attractive market opportunities at scale
Uniting science, technology and talent to get ahead of disease together

Infectious disease vaccine pipeline

44

Sales from infectious diseases

£16bn

World leader in infectious diseases

- For more than 70 years, GSK has pioneered novel research methods and technologies to help protect people from infectious diseases caused by bacteria, viruses and parasites
- Broadest portfolio in the industry and market-leading in multiple categories, e.g. shingles, meningitis, and paediatrics
- Leading biopharma company in total adult immunisation schedule with current best-in-class shingles and RSV vaccines
- World-class manufacturing, regulatory and technical expertise that create high barriers to entry
- Increasing synergies in preventing infectious disease and treating chronic conditions

Focused on earlier intervention and prevention

- Earlier intervention and prevention, and vaccination across all ages can change the course of disease and prevent serious complications
- Investment in prevention will benefit patients, society, and global economies, potentially reducing the $1 trillion lost each year in productivity by the G20 due to preventable conditions

Delivering health impact at scale

- Infectious disease portfolio will reach around half of the more than 2.5 billion people we will reach this decade

Significant societal burden leading to 1 in 6 deaths or further health complications for patients

- Approximately 330,000 older adults are hospitalised globally each year with RSV
- 1 in 3 people will develop shingles in their lifetime, sometimes with serious consequences such as long-term nerve pain and vision loss
- Seasonal influenza infects between 3-11% of people causing a significant loss in economic productivity
- There are approximately 300 million people with chronic hepatitis B, and around 900,000 deaths from liver disease-related consequences
- Anti-microbial resistance is a top-10 public health threat and caused approximately 1.3 million deaths in 2019

Infectious disease market expected to grow to £105 billion by 2028, potentially delivering resilient revenues, high margins, and profitable growth for GSK

1. Full-year 2022 sales, including vaccines, HIV, Xevudy and pandemic vaccines
7. EvaluatePharma, May 2023
World leader in infectious diseases R&D

Dr Tony Wood, Chief Scientific Officer
Four focused therapeutic areas

Two thirds of our development portfolio comes from infectious diseases and HIV

Infectious diseases
- Shingrix
- Arexvy®
- MenABCWY
- bepirovirsen
- Brexafemme
- gepotidacin
- tebipenem
- Pneumococcal 24-valent
- mRNA influenza
- Herpes simplex virus
- gonorrhoea

HIV
- Long-acting and ultra-long acting
  - Apretude®
  - N6LS (bNAb2)
  - 3rd generation INSTI4
  - Capsid inhibitor

Immunology/respiratory
- depemokimab
- Nucala (COPD5)
- GSK4532990 (NASH6)
- camlrixant

Oncology
- momelotinib
- Jemperli
- cobolimab
- CD226 axis

Advanced technology and data platforms with targeted business development

Note: select pipeline programmes shown
1. Respiratory syncytial virus in older adults
2. Long-acting injectable option for HIV prevention
3. Broadly neutralising antibody
4. Integrase strand transfer inhibitor
5. Chronic obstructive pulmonary disease
## A focused biopharma company

**Execution**
Focus on pipeline acceleration and complementary business development (assets and platforms) to deliver innovative vaccines and medicines.

**Technology**
Using platform and data technology to deliver scale innovative vaccines and medicines better and faster.

**Culture**
Building a culture that is ambitious for patients; attracting top talent, partners, and highly skilled scientists.

---

**Uniting science, technology and talent to get ahead of disease together**
Infectious diseases
A significant and growing burden to patients and society

Seasonal respiratory viruses
- Respiratory syncytial virus
  - ~330k annual older adult hospitalisations

Influenza
- ~1 billion people infected annually

SARS-CoV-2
- >750 million confirmed cases worldwide

Bacterial and fungal infections
- Meningococcal disease
  - ~2.5 million people infected annually

Pneumococcal disease
- ~1 million globally deaths annually

Urinary tract infections
- ~15 million episodes in the US annually

Chronic viral infections
- Herpes zoster virus (shingles)
  - ~1 million people in the US infected annually

Hepatitis B virus
- >300 million people living with HBV

Herpes simplex virus
- ~500 million people living with HSV

Ambition to transform the prevention and treatment of infectious diseases for billions of people

World leader in infectious diseases
Uniting science, technology and talent to get ahead of disease together

A long history of innovation leadership, with significant ambitions for growth

Infectious disease development

>70 years

New launches since 2000

>15

Pivotal trial data readouts 2023 to 2031

~22

New launches 2023 to 2031

~25

- Pioneer of novel research methods and technologies to help protect people from infectious diseases caused by bacteria, viruses and parasites
- Broadest portfolio in the industry and market leading in multiple categories, e.g. shingles, meningitis, and paediatrics
- 90% of the vaccines portfolio offers >90% efficacy
- Poised to lead in total adult immunisation schedule with current best-in-class shingles and RSV vaccines
- World-class manufacturing, regulatory and technical expertise creating high barriers to entry
- £1 billion investment in R&D to get ahead of infectious diseases in lower income countries
- Ambition is to transform the prevention and treatment of infectious diseases for billions of people given the significant and growing burden to patients and society
### World-leading infectious diseases portfolio

**Addressing a significant global health burden for society**

<table>
<thead>
<tr>
<th>Phase I - 22 assets</th>
<th>Infectious diseases</th>
<th>HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>2906496 (adjuvanted recombinant protein*) C. difficile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4429016 (adjuvanted bioconjugated recombinant protein*) K. pneumoniae</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3958329 (adjuvanted recombinant subunit) cytomegalovirus*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4382726 (mRNA*) seasonal flu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4396647 (mRNA*) COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4607584 (bivalent GMMA*) invasive non-typhoidal salmonella**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3943804 (recombinant protein, adjuvanted*) therapeutic herpes simplex virus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3536867 (bivalent conjugate*) salmonella (typhoid + paratyphoid A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2563268 (Mb cholesterol dependent inhibitor*) tuberculos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>318489 (C5K-12 inhibitor) visceral leishmaniasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>344445 (proteasome inhibitor*) visceral leishmaniasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3727270 (6- sulfonpyrazone whole cell inhibitor*) malaria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3802347 (FineN inhibitor*) uncomplicated UTI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3927388 (PARP inhibitor) viral COPD exacerbations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>418137 (anti-spike protein antibody*) COVID-19^*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>396993 (PARP/PIK inhibitor) HSP 90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5280738 (Tuberculosis) HSP 90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>401499 (Capid protein inhibitor) HIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4032484 (proteasome inhibitor*) HIV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phase II - 14 assets</th>
<th>Infectious diseases</th>
<th>HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>4403671 (live, attenuated) MMRV new strain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4536852 (MMR*) Shigella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>352886 (viral vector with recombinant protein, adjuvanted*) therapeutic hepatitis B virus***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>402330 (recombinant protein, OMV, conjugated vaccine) MenABCWY, 2nd Gen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>417876 (live, attenuated) varicella, new strain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>340796 (PAP57) adult pneumococcal disease, 24-valent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>530952 (PAP57) pseudotuberculosis meningococcal disease, 24-valent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4106647 (adjuvanted recombinant protein*) human papillomavirus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>434843 (GMMA) spanospora^*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3076640 (tetanus t-RNA synthetase inhibitor*) tuberculosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3364860 (tetanus t-RNA synthetase inhibitor*) tuberculosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>460447 (procapid protein inhibitor) HIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>465284 (procapid protein inhibitor) HIV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phase III - 8 assets</th>
<th>Infectious diseases</th>
<th>HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arexvy (adjuvanted recombinant protein) RSV older adults**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYK Covione (recombinant protein nanoparticle, adjuvanted*) COVID-19^*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gempidacin (RTI inhibitor*) uncomplicated UTI**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>beprinovir (antisense oligonucleotide*) hepatitis B virus**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVR-2482 (neutralising monoclonal antibody*) influenza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VRC-209 (drusenfarn antibody*) influenza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>380109 (bola polymerase-synthesising antibody*) influenza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3996239 (bivalent conjugate*) salmonella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3903794 (bivalent conjugate*) salmonella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3943804 (recombinant protein, adjuvanted*) therapeutic herpes simplex virus</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Recent pipeline developments

**Arexvy (RSV, older adult)**
- First company to receive approval (US, EU)
- Second season RSV data
- Additional flu co-admin data, 50-59 high-risk adults phase III data and further regulatory decisions (JP) anticipated in H2 2023

**MenABCWY**
- Phase III primary endpoints met; only 5-in-1 vaccine to demonstrate immunological effectiveness against 110 diverse MenB invasive strains
- Preliminary phase III data presented at European Society for Paediatric Infectious Diseases

**Gepotidacin**
- Potential to be the first new antibiotic class for uUTIs in over 20 years
- Positive phase III data presented at European Society of Clinical Microbiology and Infectious Diseases

---

*In-license or other alliance relationship with third party  ** Additional indications or candidates also under investigation  ^ In registration 1. In Phase I/II study  2. Transition activities underway to enable further progression by partner  3. GSK has exclusive option to co-develop post Phase II  4. Approved in US and EU  5. Collaboration with SK Bioscience, approved in Korea and UK  6. Phase III study start expected in 2023
Delivering the next wave of vaccines to address infectious disease
First or best-in-class opportunities in Phase I or Phase II clinical development

GSK3943104 for herpes simplex virus
- Leverages knowledge and expertise from herpes varicella zoster virus
- ~500 million people across the world are infected with herpes simplex virus or HSV
- 1/3 of patients with genital herpes suffer frequent outbreaks. Beyond the physical outbreaks, genital herpes is also associated with significant psychological morbidity, stigma, low quality of life and a three-fold increase in the risk of acquiring HIV
- Opportunity to transform genital herpes management by providing a superior, long-acting and simple treatment option

GSK4348413 for Neisseria gonorrhoeae
- In clinical development to prevent Neisseria gonorrhoeae infections in individuals ≥16 years, regardless of previous infection history
- Neisseria gonorrhoeae is a common sexually transmitted infection with more than half of cases occurring among young people aged 15-24 years of age
- Untreated gonorrhoea can result in chronic pain, life-threatening ectopic pregnancy and infertility and can increase the risk of getting and transmitting HIV in both women and men. An estimated 82 million new gonococcal infections occurred worldwide in 2020¹
- This asset has been granted Fast Track Designation by the US FDA underlying the pressing medical need

¹ Phase III study start expected in 2023. *Andean, Central, Southern & Tropical LATAM and Caribbean; AI/AN, American Indian and Alaska Native; EU, European Union; MSM, men who have sex with men; SEA, Southeast Asia
Leading suite of platform technologies across vaccines and medicines
Unlocking the potential to go beyond existing modalities

Breadth of platform technologies provides options for future vaccines and medicines with increasing platform synergy

Select examples

• **Next wave adjuvant:** could deliver similar potency and decreased reactogenicity to unlock new prophylactic and therapeutic fields

• **mRNA:** potential to be applied across a number of diseases; currently evaluating second-generation mRNA backbone, developed with CureVac. Positive phase I trial featuring modified mRNA monovalent vaccine candidates targeting COVID-19 and flu

• **Multiple Antigen Presenting System (MAPS):** novel and highly efficient vaccine technology platform that combines polysaccharides and proteins, potentially enables broader coverage and generating higher antibody responses – phase II 24 valent and preclinical 30-plus valent pneumococcal vaccine candidate

• **Oligonucleotides:** bepivirsen, an anti-sense oligonucleotide, is designed to recognise HBV DNA. Wave Life Sciences PRISM oligonucleotide platform includes the in-licensing of novel RNA-editing oligonucleotides

• **Protein engineering:** for multiple auto-immune diseases that are advancing through preclinical phases
A new technology era advancing human biological science
AI/ML is characterising disease and accelerating the discovery of novel medicines

Discovery and preclinical

>80%
Preclinical targets have genetic evidence

Clinical development

75%
Clinical development targets have genetic evidence

- >40 joint research projects through 23andMe
- Large-scale foundational datasets to improve target validation and translation
- Computational biology to support the positioning of bi-specifics

Using machine learning generating deep insights for bepirovirsen

- Machine learning models are identifying patient profiles that are indicative of clinical and biological trajectories
- Proprietary algorithms are predicting future response for bepirovirsen
- Uncovered five distinct patient subtypes in response to bepirovirsen treatment, including a subtype enriched for responders and a mixed response subtype
- Nearly doubled precision in patient response trajectory prediction versus traditional virological marker HBsAg

Status: published positive B-Clear phase IIb results. Started B-Well 1 and B-Well 2 phase III trials in Q1 2023. B-Together phase IIb data readout H2 2023
Science and technology hold the key to transforming medical discovery
Continued pipeline productivity improvements are delivering new treatments

Success rates\(^1\) in phase II have improved to median with phase III and registration upper quartile

End to end cycle times have improved by 20% compared to industry median since 2016 helped by vaccines performance

- Vaccine cycle times are faster, and success rates higher relative to the pharmaceutical industry benchmark
- Overall performance has been improving over the years on a background of increasing industry cycle times and has now surpassed the three-year rolling industry average (GSK 9.6 years versus industry 11.4 years)

End to end cycle times have decreased by 3.7 years

R&D late-stage success rates, three-year rolling trend

Source: CMR Clarivate Analytics, 2022. Rolling three year trend. 1. Industry median and top quartile values are based on major companies only (those spending ≥US$ 2 billion in 2021 on pharmaceutical R&D)
Delivering profitable growth to 2026 and beyond

Luke Miels, Chief Commercial Officer
Delivering double-digit growth

Infectious diseases represented more than 50% of full-year 2022 sales

Sales from infectious diseases\(^1\)

£16bn

+12% CAGR\(^2\)

1. Full-year 2022 sales, including vaccines, HIV, Xevudy and pandemic vaccines.

2. Compound annual growth rate 2016 to 2022 based on reported sales.
Infectious disease is an attractive and growing market
A significant and growing burden to patients and society

Market size by 2028

£105bn

Seasonal respiratory viruses
- Respiratory syncytial virus
  - 2021: £1bn, 2028: £6bn, +42% CAGR
- Influenza
  - 2021: £5bn, 2028: £8bn, +8% CAGR
- SARS-CoV-2
  - 2021: £50bn, 2028: £18bn, -13% CAGR

Bacterial and fungal infections
- Meningococcal disease
  - 2021: £2bn, 2028: £3bn, +17% CAGR
- Pneumococcal disease
  - 2021: £5bn, 2028: £7bn, +6% CAGR
- Urinary tract infections
  - 2021: £0.2bn, 2028: £0.8bn, +26% CAGR

Chronic viral infections
- Shingles
  - 2021: £2bn, 2028: £5bn, +17% CAGR
- Chronic hepatitis B
  - 2021: £2bn, 2028: £4bn, +11% CAGR
- Human immunodeficiency virus
  - 2021: £20bn, 2028: £25bn, +3% CAGR

Source: EvaluatePharma, May 2023
Transformed commercial capabilities
Building blockbuster treatments in infectious diseases

Delivering competitive launches and driving mid-cycle growth

• Improved sales force effectiveness across key markets, including China
• Deployed digital and predictive analytics to further enhance outcomes

Shingrix
• Large population of unvaccinated individuals remains. Now launched in 31 of markets that represent ~90% of the vaccine market by value

Meningitis
• Increased focus on educating physicians and parents about the devastating impact of Men B and the strong protection they can expect from our vaccine, supported by newly available real-world evidence.

**Shingrix sales**
£3.0bn
+72% AER, +60% CER

**Meningitis sales**
£1.1bn
+16% AER, +11% CER
# Commitment to growth

GSK on track to deliver profitable growth to 2026 and through the decade

<table>
<thead>
<tr>
<th>Seasonal respiratory viruses</th>
<th>Bacterial and fungal infections</th>
<th>Chronic viral infections</th>
</tr>
</thead>
</table>

蔺

[^1]: Arexvy
[^2]: Non-risk adjusted peak year sales potential is subject to certain assumptions consistent with those for previous outlooks, ambitions and expectations
[^3]: Influenza
[^4]: Meningococcal disease
[^5]: Anti-infectives
[^6]: Pneumococcal disease
[^7]: ~£2bn in peak year sales[^2]

What's next...

<table>
<thead>
<tr>
<th>Disease</th>
<th>Next Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory syncytial virus</td>
<td>• Additional flu co-admin data, 50-59 high-risk adults phase III data and further regulatory decisions (JP) in H2 2023</td>
</tr>
<tr>
<td>Influenza</td>
<td>• Phase I/II trial for multivalent vaccine candidates underway. Phase III data 2025+. Combination life-cycle management strategy</td>
</tr>
<tr>
<td>Meningococcal disease</td>
<td>• MenABCWY 2nd gen phase II data H2 2023. Pentavalent MenABCWY adolescents regulatory submission (US) in 2024. Pentavalent MenABCWY infants regulatory submission in 2025+</td>
</tr>
<tr>
<td>Pneumococcal disease</td>
<td>• 24-valent adult phase III start in 2024. Phase III data 2025+. Paediatrics launch before the end of the decade 30-plus valent adult advanced to the clinic in 2024</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>• Preparing US and EU regulatory submissions for gepotidacin</td>
</tr>
<tr>
<td></td>
<td>• Start phase III trial in 2023 for tebipenem</td>
</tr>
<tr>
<td></td>
<td>• Relaunch Brexafemme for VVC and rVVC in US</td>
</tr>
<tr>
<td>Herpes zoster (shingles)</td>
<td>• Multi-billion sales through the decade, global expansion, incl. China. Life-cycle management opportunities (population expansion, booster, dementia)</td>
</tr>
<tr>
<td>Hepatitis B virus</td>
<td>• B-Together phase IIb data H2 2023</td>
</tr>
<tr>
<td></td>
<td>• B-WELL phase III data 2025+</td>
</tr>
</tbody>
</table>

[^1]: Arexvy
[^2]: Non-risk adjusted peak year sales potential is subject to certain assumptions consistent with those for previous outlooks, ambitions and expectations
[^3]: Influenza
[^4]: Meningococcal disease
[^5]: Anti-infectives
[^6]: Pneumococcal disease
[^7]: ~£4bn in peak year sales[^2]

[^1]: Affinavax (incl. 24 and 30-plus valent in paediatrics and adults) 6 gepotidacin, tebipenem HBr and Brexafemme 7 Shingrix 8 bepiroviren
[^2]: mRNA seasonal influenza and combinations
[^3]: Additional sales from MenABCWY

GSK
World leader in infectious diseases delivering profitable growth to 2026 and through the decade

- Broadest portfolio in the industry with market leading in multiple categories, e.g. shingles, meningitis, and paediatrics
- 90% of the vaccines portfolio offers >90% efficacy
- Poised to lead in total adult immunisation schedule with current best-in-class shingles and RSV vaccines
- Vaccinate 40% of the world’s children and helped drive the adult vaccine market with ground-breaking shingles vaccine
- World-class manufacturing, regulatory and technical expertise creating high barriers to entry
- Ambition is to transform the prevention and treatment of infectious diseases for billions of people given the significant and growing burden to patients and society

Infectious disease market growing to £105 billion by 2028

<table>
<thead>
<tr>
<th>Infectious disease sales&lt;sup&gt;1&lt;/sup&gt; full-year 2022</th>
<th>Pivotal trial data readouts 2023+</th>
<th>New launches 2023+</th>
</tr>
</thead>
<tbody>
<tr>
<td>£16bn</td>
<td>~22</td>
<td>~25</td>
</tr>
</tbody>
</table>

Potentially delivering resilient revenues, high margins, and profitable growth for GSK

1. Full-year 2022 sales, including vaccines, HIV, Xevudy and pandemic vaccines
Getting ahead of infectious diseases with GSK management

Four Q&A-focused, virtual breakout sessions

Seasonal respiratory viruses
Session 1: 14:30-15:00 BST
Session 2: 15:15-15:45 BST
Phil Dormitzer
Christi Kelsey
Luke Miels

Bacterial and fungal infections
Session 1: 14:30-15:00 BST
Session 2: 15:15-15:45 BST
Kumaran Vadivelu
Rob Bowers
David Redfern

Chronic viral infections
Session 1: 14:30-15:00 BST
Session 2: 15:15-15:45 BST
Chris Corsico
Lizzie Champion
James Greenhalgh
Tony Wood

Delivering health impact at scale
Session 1: 14:30-15:00 BST
Session 2: 15:15-15:45 BST
Deborah Waterhouse
Thomas Breuer

IR: jeffrey_r_mclaughlin@gsk.com
IR: joshua_x_williams@gsk.com
IR: mick_j_readey@gsk.com
IR: frances_p_defranco@gsk.com
Use of GSK conference call, webcast and presentation slides
The GSK plc webcast, conference call and presentation slides (together the ‘GSK materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the GSK materials in any way. You may not edit, alter, adapt or add to the GSK materials in any way, nor combine the GSK materials with any other material. You may not download or use the GSK materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the GSK materials. You may not use the GSK materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. GSK plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Telephone +44 20 8047 5000, www.gsk.com